Oruka COO sells 600 shares to cover RSU taxes

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an automatic sale of 600 shares of common stock at $41.30 per share.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported an automatic sale of 600 shares of common stock at $41.30 per share. The footnote explains that these sales were made under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding obligations from vesting restricted stock units. After this tax-related sale, Sandler directly holds 236,984 shares of Oruka common stock.

Insider Trade Summary

Net Seller: 600 shares

Net Sell 1 txn

Insider Sandler Laura Lee

Role Chief Operating Officer

Sold 600 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock	600	$41.30	$25K

Holdings After Transaction: Common Stock — 236,984 shares (Direct)

Footnotes (1)

1. F1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oruka Therapeutics (ORKA) report for Laura Lee Sandler?

Oruka Therapeutics reported that COO Laura Lee Sandler sold 600 shares of common stock at $41.30 per share. The sale was an automatic, non-discretionary sell-to-cover transaction to pay tax withholding arising from vesting restricted stock units.

Was the Oruka Therapeutics (ORKA) insider sale by Laura Lee Sandler discretionary?

No. The filing states the reported sales were executed under Oruka Therapeutics’ automatic, non-discretionary sell-to-cover procedure. This means the 600 shares were sold solely to satisfy tax withholding obligations from restricted stock unit vesting, not as a discretionary open-market trade.

How many Oruka Therapeutics (ORKA) shares did Laura Lee Sandler sell and at what price?

Laura Lee Sandler sold 600 shares of Oruka Therapeutics common stock at $41.30 per share. The transaction was coded as a sale but is described as an automatic sell-to-cover for tax withholding related to vesting restricted stock units.

How many Oruka Therapeutics (ORKA) shares does Laura Lee Sandler hold after the reported Form 4 transaction?

Following the tax-related sale, Laura Lee Sandler directly holds 236,984 shares of Oruka Therapeutics common stock. This post-transaction balance reported in the filing shows she retains a substantial equity position after selling 600 shares to cover tax obligations.

What does “sell-to-cover” mean in the Oruka Therapeutics (ORKA) Form 4 footnote?

In this context, “sell-to-cover” means a portion of vested restricted stock units is automatically sold to pay required tax withholding. For Oruka Therapeutics, 600 shares were sold under an automatic, non-discretionary procedure specifically to satisfy tax liabilities from RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandler Laura Lee

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		600	D	$41.3	236,984	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

	/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.